Home › Funds › Parkman Healthcare Partners LLC › BSX

Parkman Healthcare Partners LLC position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Parkman Healthcare Partners LLC reported holding 180,481 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q2 2026 13F filing — a position valued at US$7.7M, representing 0.79% of its reported portfolio and ranking #46 among its reported holdings. Parkman Healthcare Partners LLC has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)180.48K sh
Reported value held$7.70M
Portfolio Weight0.79%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's BSX position evolved

Parkman Healthcare Partners LLC first disclosed a stake in BSX in Q3 2023 at 597,260 shares (US$31.5M). The position peaked in Q4 2025 at 500,529 shares, worth US$47.7M. Across 12 filings, Parkman Healthcare Partners LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 180,481 shares valued at US$7.7M — a reduction of -268,287 shares quarter over quarter.. Notable position changes include a 35% trim in Q1 2024 (shares rose 12% over the following quarter), a 53% increase in Q3 2025 (shares fell 2% over the following quarter), a 60% trim in Q2 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 597.26K $31.54M New
Q4 2023 652.80K $37.74M Add
Q1 2024 425.47K $29.14M Reduce
Q2 2024 551.59K $42.48M Add
Q3 2024 447.20K $37.48M Reduce
Q4 2024 337.35K $30.13M Reduce
Q1 2025 225.99K $22.80M Reduce
Q2 2025 283.17K $30.41M Add
Q3 2025 434.38K $42.41M Add
Q4 2025 500.53K $47.73M Add
Q1 2026 448.77K $28.16M Reduce
Q2 2026 180.48K $7.70M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include Banque Cantonale Vaudoise (US$2.89B), PRIMECAP MANAGEMENT CO/CA/ (US$2.16B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held BSX?

Parkman Healthcare Partners LLC has disclosed BSX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Parkman Healthcare Partners LLC's current position in BSX?

As of Q2 2026, Parkman Healthcare Partners LLC holds 180.48K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $7.70M, representing 0.79% of its reported portfolio and ranking #46.

Has Parkman Healthcare Partners LLC been buying or selling BSX?

In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC reduced its position in BSX. The position peaked in Q4 2025 at 500.53K shares.

Which other funds hold BSX?

Other major institutional holders of BSX include Banque Cantonale Vaudoise, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.